Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2582204 | 0.92 | EGLN1 (0.60) | HIF1AEGLN1 | |
| SCHEMBL2577054 | 0.89 | EGLN1 (0.53) | HIF1AEGLN1 | |
| SCHEMBL2574737 | 0.89 | EGLN1 (0.52) | HIF1AEGLN1 | |
| SCHEMBL2577170 | 0.88 | EGLN1 (0.54) | HIF1AEGLN1 | |
| SCHEMBL2585485 | 0.87 | EGLN1 (0.51) | HIF1AEGLN1 | |
| SCHEMBL2583340 | 0.86 | EGLN1 (0.56) | HIF1AEGLN1 | |
| SCHEMBL2582697 | 0.85 | HIF1A (0.51) | HIF1AEGLN1 | |
| SCHEMBL3828049 | 0.85 | EGLN1 (0.49) | HIF1AEGLN1 | |
| SCHEMBL2582349 | 0.85 | EGLN1 (0.60) | HIF1AEGLN1 | |
| SCHEMBL2574649 | 0.84 | HIF1A (0.53) | HIF1AEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048892-B2 | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-11-01 | — | — | US | claimed |
| EP-2097416-B1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2097416-B1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8048892-B2 | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048892-B2 | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048892-B2 | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20090111806-A1 | Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111806-A1 | Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111806-A1 | Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2008076425-A1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111806-A1 | Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof | EGLN3, EGLN2, HIF1AN | HIF1A 6/4885EGLN1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.